

SEQUENCE LISTING

<110> Lima, Christopher  
Mossessova, Elena

<120> Structure-Based Drug Design for Ulp1 Protease Substrates

<130> 2650/1G681-US1

<140> TBA

<141> Concurrently Herewith

<150> 60/205,336

<151> 2000-05-18

<160> 2

<170> PatentIn version 3.0

<210> 1

<211> 1866

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 1

atgtcagttg aagtagataa gcaccggaac acactacagt atcataaaaa gaacccttac	60
tcccctttat tctccccaat ttctacatat aggtgttatc ctcggttatt gaacaatccc	120
tccgagtcta gaagatcagc cagttttagt ggtatttata aaaaaagaac caatacgtca	180
agattcaatt atttaaacga ccgccgtgtt ttatcaatgg aagaatcaat gaaagatggg	240
tcagatagag ctagtaaagc tggttttata ggaggcataa gagaaactct ttggaactca	300
ggtaagtact tatggcacac atttgtgaaa aacgaacctc gcaattttga tggttctgaa	360
gtagaagcaa gtggtaacag cgacgttgag agcagaagtt ctggaagtag gagcagtgac	420
gtaccatatg gtctacgtga aaattattcc tcggatacaa gaaaacacaa attcgatacg	480
tcgacgtggg ccttaccaaa taaaaggaga agaatcgaaa gtgaagggtgt ggggacacct	540
tcaacctcac caatcagctc tttggcttct caaaaaagca attgtgatag tgacaatagc	600
ataacttttt cgagagatcc ttttggttgg aataagtgga aaacaagtgc tattggttct	660
aactcagaaa ataacacttc tgatcagaaa aatagctacg acaggcgaca gtatgggaca	720
gcctttatta gaaagaaaaa agttgcaaaa cagaacatta acaatactaa actggtgtcg	780



20

25

30

Tyr Pro Arg Val Leu Asn Asn Pro Ser Glu Ser Arg Arg Ser Ala Ser  
 35 40 45

Phe Ser Gly Ile Tyr Lys Lys Arg Thr Asn Thr Ser Arg Phe Asn Tyr  
 50 55 60

Leu Asn Asp Arg Arg Val Leu Ser Met Glu Glu Ser Met Lys Asp Gly  
 65 70 75 80

Ser Asp Arg Ala Ser Lys Ala Gly Phe Ile Gly Gly Ile Arg Glu Thr  
 85 90 95

Leu Trp Asn Ser Gly Lys Tyr Leu Trp His Thr Phe Val Lys Asn Glu  
 100 105 110

Pro Arg Asn Phe Asp Gly Ser Glu Val Glu Ala Ser Gly Asn Ser Asp  
 115 120 125

Val Glu Ser Arg Ser Ser Gly Ser Arg Ser Ser Asp Val Pro Tyr Gly  
 130 135 140

Leu Arg Glu Asn Tyr Ser Ser Asp Thr Arg Lys His Lys Phe Asp Thr  
 145 150 155 160

Ser Thr Trp Ala Leu Pro Asn Lys Arg Arg Arg Ile Glu Ser Glu Gly  
 165 170 175

Val Gly Thr Pro Ser Thr Ser Pro Ile Ser Ser Leu Ala Ser Gln Lys  
 180 185 190

Ser Asn Cys Asp Ser Asp Asn Ser Ile Thr Phe Ser Arg Asp Pro Phe  
 195 200 205

Gly Trp Asn Lys Trp Lys Thr Ser Ala Ile Gly Ser Asn Ser Glu Asn  
 210 215 220

Asn Thr Ser Asp Gln Lys Asn Ser Tyr Asp Arg Arg Gln Tyr Gly Thr  
 225 230 235 240

Ala Phe Ile Arg Lys Lys Lys Val Ala Lys Gln Asn Ile Asn Asn Thr  
 245 250 255

Lys Leu Val Ser Arg Ala Gln Ser Glu Glu Val Thr Tyr Leu Arg Gln  
 260 265 270

Ile Phe Asn Gly Glu Tyr Lys Val Pro Lys Ile Leu Lys Glu Glu Arg  
 275 280 285



Gly Glu Asp Phe Asp Leu Ile His Leu Asp Cys Pro Gln Gln Pro Asn  
565 570 575

Gly Tyr Asp Cys Gly Ile Tyr Val Cys Met Asn Thr Leu Tyr Gly Ser  
580 585 590

Ala Asp Ala Pro Leu Asp Phe Asp Tyr Lys Asp Ala Ile Arg Met Arg  
595 600 605

Arg Phe Ile Ala His Leu Ile Leu Thr Asp Ala Leu Lys  
610 615 620

TCF300